Invitrocue (Hong Kong) Ltd is a subsidiary of Invitrocue Pte Ltd, Singapore. Invitrocue Group is an innovative life sciences company that supports decision making for the healthcare and pharmaceutical industry using its proprietary 3D cell culture technology. The Group currently operates in Germany, Spain, Brazil, Hong Kong, Mainland China and Singapore.
The Hong Kong lab facility is located at the Hong Kong Science and Technology Park, offering in vitro personalised clinical oncology tests for chemotherapeutic and targeted drugs in resistance and sensitivity through its Onco-PDO™ platform. It also uses the same platform for pharmacology testing services to biotechnology and pharmaceutical companies for new compounds against cancer.
The facility in Hong Kong provides Invitrocue with better access to the network of supportive early adopters of its unique Onco-PDO technology in the region. This includes primarily oncologists and hospitals based in Hong Kong and opportunities in Mainland China and Macao.
